Tikva Allocell Pte Ltd CEO, Ivan Horak and CFO, Wilson Cheung (張偉遜) will be presenting at the 3rd BioCentury-BayHelix East-West Biopharma Summit 2024: Singapore.
For more information on the event, please visit https://conferences.biocentury.com/east-west-summit.
SINGAPORE and UNITED STATES — 22 JULY 2026 — Tikva Allocell today announced the successful closing of an $8 million Series
CAR-T cell therapy has revolutionized cancer treatment, but its efficacy against solid tumors remains limited due to challenges like poor CAR-T cell in-vivo survival. Tikva’s engineered SB9 EBVST platform will not only address a major resistance mechanism axis but also opens doors to more effective CAR T cell therapies for solid tumors.